Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | GPR6 | P46095 | 3/20 | 0.37 |
| ▸ | MLNR | O43193 | 4/20 | 0.36 |
| ▸ | MC4R | P32245 | 2/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359551 | 1.00 | BTK (0.39) | BTKGPR6MLNRMC4RBDKRB1 | |
| SCHEMBL20365237 | 0.93 | EPHX2 (0.40) | BTKMLNRPIK3CDPIK3CA | |
| SCHEMBL20359117 | 0.90 | BTK (0.44) | BTK | |
| SCHEMBL20359114 | 0.90 | BTK (0.44) | BTK | |
| SCHEMBL20360088 | 0.90 | MC4R (0.38) | BTKGPR6MLNRMC4RPIK3CD | |
| SCHEMBL20360092 | 0.90 | MC4R (0.38) | BTKGPR6MLNRMC4RPIK3CD | |
| SCHEMBL20358811 | 0.88 | BTK (0.40) | BTKMC4RBDKRB1 | |
| SCHEMBL20358805 | 0.88 | BTK (0.40) | BTKMC4RBDKRB1 | |
| SCHEMBL20358600 | 0.87 | BTK (0.41) | BTK | |
| SCHEMBL20359592 | 0.87 | BTK (0.47) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | BTK 1/4885GPR6 3328/4885MLNR 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.